MiR-34a-Functionalized Hydroxyapatite by Lyophilization Promoted Bone Regeneration in Irradiated Bone Defects

IF 3.1 3区生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Journal of Tissue Engineering and Regenerative Medicine Pub Date : 2023-09-11 DOI:10.1155/2023/9946012

Xi Wu, Xiaoke Feng, Gang Zhang, Huan Liu

引用次数: 0

Abstract

The rehabilitation of bone defects after radiotherapy requires the development of osteoinductive bone substitutes. MicroRNA could be used as an osteogenic factor to fabricate functional materials for bone regeneration. In this study, we used miR-34a to enhance bone regeneration after irradiation. We lyophilized lipofectamine-agomiR-34a lipoplexes on hydroxyapatite (HA) to develop miR-34a-functionalized hydroxyapatite (HA-agomiR-34a). The morphology was observed by scanning electron microscope and atomic force microscope. Fluorescence microscopy confirmed the retention of agomiR-34a on the surface of HA. HA-agomiR-34a showed high transfection efficiency and good biocompatibility. HA-agomiR-34a enhanced the osteoblastic differentiation of radiation-impaired bone marrow stromal cells (BMSCs). Implantation of HA-agomiR-34a promoted bone regeneration in irradiated bone defects. HA-agomiR-34a may be a novel and safe bone substitute to promote the reconstruction of bone defects after radiotherapy.

查看原文本刊更多论文

冻干mir -34a功能化的羟基磷灰石促进辐照骨缺损的骨再生

放射治疗后骨缺损的修复需要骨诱导替代物的发展。MicroRNA可作为成骨因子用于骨再生功能材料的制备。在本研究中，我们使用miR-34a促进辐照后骨再生。我们冻干脂质体- agomir -34a在羟基磷灰石(HA)上形成mir -34a功能化的羟基磷灰石(HA- agomir -34a)。用扫描电镜和原子力显微镜观察其形貌。荧光显微镜证实在HA表面有agomiR-34a的保留。HA-agomiR-34a转染效率高，生物相容性好。HA-agomiR-34a增强了辐射损伤的骨髓基质细胞(BMSCs)的成骨分化。植入HA-agomiR-34a促进辐照骨缺损的骨再生。HA-agomiR-34a可能是一种新型安全的骨替代物，可促进放疗后骨缺损的重建。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Tissue Engineering and Regenerative Medicine 生物-工程：生物医学

CiteScore

7.50

自引率

3.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Journal of Tissue Engineering and Regenerative Medicine publishes rapidly and rigorously peer-reviewed research papers, reviews, clinical case reports, perspectives, and short communications on topics relevant to the development of therapeutic approaches which combine stem or progenitor cells, biomaterials and scaffolds, growth factors and other bioactive agents, and their respective constructs. All papers should deal with research that has a direct or potential impact on the development of novel clinical approaches for the regeneration or repair of tissues and organs. The journal is multidisciplinary, covering the combination of the principles of life sciences and engineering in efforts to advance medicine and clinical strategies. The journal focuses on the use of cells, materials, and biochemical/mechanical factors in the development of biological functional substitutes that restore, maintain, or improve tissue or organ function. The journal publishes research on any tissue or organ and covers all key aspects of the field, including the development of new biomaterials and processing of scaffolds; the use of different types of cells (mainly stem and progenitor cells) and their culture in specific bioreactors; studies in relevant animal models; and clinical trials in human patients performed under strict regulatory and ethical frameworks. Manuscripts describing the use of advanced methods for the characterization of engineered tissues are also of special interest to the journal readership.